Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.61 | N/A | +2.04% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.61 | N/A | +2.04% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management conveyed a cautious optimism regarding future developments. They emphasized their focus on innovative therapies but did not provide specific revenue or earnings guidance.
Management highlighted ongoing commitment to innovation in therapies.
They expressed confidence in their pipeline despite not providing specific guidance.
The earnings report shows that United Therapeutics exceeded EPS expectations, which is a positive sign for the company. However, the stock fell by 1.44%, likely due to the lack of revenue data and guidance. Investors may be concerned about the company's future performance without clear direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CANADIAN NATL RY CO
Apr 24, 2017